Preferences and Health-Related Quality-of-Life Related to Disease and Treatment Features for Patients with Hemophilia A in a Canadian General Population Sample

Figures & data

Table 1 Mean and 95% Confidence Intervals (CI) for Utility and Visual Analogue Scale (VAS) Results

	Mean (95% CI)
	Utility	VAS
A. On demand; ABR=36	0.70 (0.65–0.76)	56.2 (52.9–59.5)
B. Intravenous prophylaxis; 2–3 infusions per week; ABR=4–5	0.81 (0.78–0.85)	71.1 (68.3–73.9)
C. Intravenous prophylaxis; 2–3 infusions per week; ABR=10	0.78 (0.73–0.82)	67.1 (64.1–70.0)
D. Intravenous prophylaxis w/daily infusions; ABR=4–5	0.74 (0.69–0.80)	63.7 (59.8–67.6)
E. Subcutaneous prophylaxis Q1W; ABR=1–2	0.90 (0.87–0.93)	81.6 (78.9–84.2)
F. Subcutaneous prophylaxis Q4W; ABR=1–2	0.91 (0.88–0.94)	84.5 (82.0–87.1)

Abbreviations: ABR, annual bleed rate; CI, confidence interval; Q1W, once weekly injection; Q4W, once monthly injection; VAS, visual analogue scale.

Figure 1 Mean and 95% confidence intervals (CI) for (A) utility and (B) visual analogue scale (VAS) results.

Table 2 Regression Coefficients in Random-Intercept Analysis of Utilities and Visual Analogue Scale (VAS) Results

	Utilities		VAS
	Coefficient	p-value	Coefficient	p-value
Intercept	0.80	<0.001	69.94	<0.001
Bleeds per year	−0.003	<0.001	−0.40	<0.001
Subcutaneous treatment*	0.11	<0.001	13.58	<0.001

Note: *vs reference category of intravenous infusions.

Abbreviation: VAS, visual analogue scale.

Table 3 Regression Coefficients in Random-Intercept Analysis of Utilities on the Frequency of Injections/Infusions

	Intravenous		Subcutaneous
	Coefficient	p-value	Coefficient	p-value
Intercept	0.86	<0.001	0.91	<0.001
Prophylactic treatments per year	−0.0003	<0.001	−0.0002	0.22

Abbreviation: VAS, visual analogue scale.